When the Pores and skin Speaks First: A Uncommon Case of Drug-Induced Candy’s Syndrome from Inhaled Remedy
It started with a soundless cry — not from the lungs, however from the pores and skin. When a 55-year-old girl arrived on the clinic complaining of painful, pink facial lesions, there was no rapid purpose to suspect something greater than a gentle pores and skin response. But what unfolded would turn into a medical anomaly — a uncommon presentation of Candy’s syndrome, not triggered by an antibiotic or antiepileptic, however by one thing few would think about: an inhaled bronchodilator capsule.
Preliminary Presentation
The affected person was a 55-year-old feminine with a longstanding historical past of hypertension and persistent obstructive pulmonary illness (COPD). She was a present smoker, averaging ten cigarettes per day, and had been on steady therapy with enalapril (for six years) and inhaled formoterol (for 2 years) with out issues.
Resulting from a latest worsening of her COPD signs, her pulmonologist switched her remedy to a twin bronchodilator: a mix of indacaterol and glycopyrronium in capsule kind, delivered through inhalation.
Two days after beginning the brand new inhaler, she offered on the Major Care clinic with:
- Painful, erythematous plaques on her cheeks and neck
- A low-grade fever
- Normal malaise
She denied utilizing new skincare merchandise, had made no dietary adjustments, and reported no latest infections. Solar publicity had been minimal, and he or she had used sunscreen constantly.
Escalation and Referral
Given the fast onset and inflammatory look of the lesions, the Major Care doctor referred her urgently to Dermatology. There, the workforce suspected a systemic inflammatory situation and really useful:
- Quick discontinuation of the brand new inhaler
- Initiation of systemic corticosteroids
- Laboratory testing, together with a full blood rely and autoimmune panel
- Pores and skin biopsy from an lively lesion
Over the subsequent 48 hours, her signs started to subside. The erythematous plaques lightened in colour, and her facial ache diminished.
Diagnostic Findings
Bloodwork revealed leukocytosis with marked neutrophilia.
Autoimmune panel: Unfavourable for ANA, anti-dsDNA, lupus anticoagulant, and different connective tissue markers.
Pores and skin biopsy: Confirmed dense neutrophilic infiltration of the dermis with no proof of vasculitis.
Twenty days later, the biopsy confirmed the medical suspicion: Candy’s syndrome, also called acute febrile neutrophilic dermatosis.
Understanding Candy’s Syndrome
Candy’s syndrome is a uncommon inflammatory situation that presents with:
- Sudden onset of painful, erythematous plaques or nodules
- Fever and systemic signs
- Elevated white blood cell counts
- Histopathology displaying dermal neutrophilic infiltration with out vasculitis
Triggers are sometimes infections, malignancies, autoimmune issues, or drugs — sometimes systemic medication like antibiotics, colony-stimulating components, or immunosuppressants.
Nevertheless, this case is outstanding: the presumed set off was an inhaled remedy. Thus far, no recognized reviews have clearly linked indacaterol/glycopyrronium with Candy’s syndrome, making this a possible first documented affiliation.
Differential Analysis
Preliminary concerns included:
- Allergic contact dermatitis
- Phototoxic response
- Lupus erythematosus
- Drug-induced toxicoderma
- Rosacea flare with systemic signs
Nevertheless, the sample of painful, raised plaques accompanied by systemic indicators and histological findings allowed these to be dominated out.
Therapy and Final result
- Discontinuation of the suspected agent
- A brief course of oral corticosteroids
This method led to fast medical enchancment, with full decision of the pores and skin lesions inside one week. No recurrence was famous on follow-up.
Scientific Implications
This case underscores a number of key classes for clinicians:
Candy’s syndrome ought to stay within the differential when new-onset, painful pores and skin lesions with systemic signs observe remedy adjustments.
Even inhaled therapies — sometimes thought of low-risk for systemic unwanted side effects — can set off uncommon immunologic reactions.
Immediate dermatological referral, pores and skin biopsy, and early corticosteroid initiation can result in full restoration.
An intensive remedy historical past, together with adjustments in supply strategies (e.g., from inhaler to capsule), is essential.
Importantly, Candy’s syndrome can even sign underlying malignancy or autoimmune illness, so broader systemic analysis is warranted in each case.
Moral Declarations
Human & Animal Safety: No experimental procedures had been carried out on people or animals.
Confidentiality: Affected person identification and private information have been absolutely protected in accordance with medical moral requirements.
Knowledgeable Consent: The affected person supplied written consent for the publication of this medical case.
Conclusion
This case highlights a uncommon and probably first-reported occasion of Candy’s syndrome triggered by an inhaled bronchodilator capsule. It challenges assumptions in regards to the systemic security of inhaled therapies and reinforces the necessity for vigilance when evaluating pores and skin reactions after any remedy change.
For Major Care physicians, it’s a reminder that generally a pink rash isn’t only a rash — it’s the immune system sounding an alarm. And on this case, the warning got here not from the lungs, however by the pores and skin.
Please SHARE this text with your loved ones and pals on Fb.
Animalsmeal
Love and Peace
